CTI BioPharma’s COVID-19 Candidate Misses Primary Endpoint Mark In Phase 2 Trial
CTI BioPharma Corp (NASDAQ:CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT…
CTI BioPharma Announces Topline Data From Final Analysis Of PRE-VENT Clinical Trial Evaluating Pacritinib As Treatment For Severe COVID-19
https://www.prnewswire.com/news-releases/cti-biopharma-announces-topline-data-from-final-analysis-of-the-pre-vent-clinical-trial-evaluating-pacritinib-as-a-treatment-for-severe-covid-19-301390078.html
CTI BioPharma Corp. And DRI Healthcare Trust Announce $135M In Debt And Royalty Transactions
CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) and DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt
BTIG Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $7
BTIG analyst Robert Hazlett initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Buy rating and announces Price Target of $7.
CTI BioPharma Q2 EPS $(0.21), Inline
CTI BioPharma (NASDAQ:CTIC) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 10.53 percent decrease over losses of $(0.19) per share from the same period last year.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.